DELCATH SYSTEMS INC
PharmaDELCATH SYSTEMS INC is a pharmaceutical company focused on Oncology, Ophthalmology, Gastroenterology. Key products include HEPZATO.
DELCATH SYSTEMS INC's Key Drugs
DELCATH SYSTEMS INC's core commercial portfolio centers on HEPZATO, spanning Oncology and Ophthalmology — its most strategically important drugs approved in the last 15 years.
DELCATH SYSTEMS INC's Recent FDA Approvals
New NDA/BLA approvals for DELCATH SYSTEMS INC over the last two years — novel drugs only, excluding generics and label supplements.
DELCATH SYSTEMS INC's Therapeutic Areas
DELCATH SYSTEMS INC's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Ophthalmology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
DELCATH SYSTEMS INC's Top Competitors
DELCATH SYSTEMS INC's closest competitors by therapeutic-area and drug-target overlap include Novartis, AbbVie, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
DELCATH SYSTEMS INC Pipeline Snapshot
DELCATH SYSTEMS INC has 7 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 5 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • HEPZATO leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 1/1 completed
- • Speed: N/A months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2023-08-14
- Latest
- 2026-05-28
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges